Barriers to Clinical Trial Efficiency and Patient Access
Clinical trial inefficiency and lack of patient access to novel therapies have been identified as key barriers to successful heart failure innovation.
Clinical Trials in the Landscape of COVID-19
The HF Collaboratory Statement provides recommendations on HF clinical trials by outlining a number of guiding principles and possible trial conduct solutions for the COVID-19 pandemic.
Improving Heart Failure Therapeutics Development in the United States
Summarizes the discussions, challenges and opportunities, and makes recommendations to achieve improved efficiency in clinical trials and the development of effective heart failure therapies.
Changing the Research Culture in the United States
Dr O’Connor & Dr Bristow’s article further highlights the importance of what changes the HF Collaboratory are working towards.
Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials
The article published in JAMA Cardiology discusses the under representation of these groups in clinical trials.
Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development
The article published in JACC details the creation of a core CRF electronic form which is now freely available for use in clinical trials to improve clinical trial efficiency in HF drug and device development in the United States.
Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Contransporter 2 Inhibitors in Patients
The white paper published in Circulation summarizes the discussions and key takeaway messages from the meeting on this topic at the FDA meeting on March 6, 2019.